ACTU
USDActuate Therapeutics Inc. Common stock
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$6.500
고가
$6.660
저가
$6.461
거래량
0.02M
기업 기본 정보
시가총액
153.2M
산업
생명공학
국가
United States
거래 통계
평균 거래량
0.07M
거래소
NGM
통화
USD
52주 범위
관련 뉴스
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics with a Buy and maintains $20 price target.
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock
CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for
Actuate Therapeutics Announces Proposed Public Offering of Common Stock
CHICAGO and FORT WORTH, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for
관련 주식
최신 정보 받기
가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기